Articles tagged with Prostate Cancer
A study of 501 patients with recurrent prostate cancer found that salvage radiotherapy can be effective for patients with high-grade disease and rapid PSA doubling time, suggesting it may prevent metastatic disease progression. The study's findings support early treatment for these patients, who are at the highest risk of disease spread.
Researchers have developed a gene expression profiling method that predicts clinical outcome in prostate cancer patients. The study's findings suggest that this approach can improve our ability to stratify patient populations and optimize disease treatment.
A new biomarker, EPCA, has been discovered that can detect prostate cancer earlier than traditional methods. The marker is expressed in the tumor and throughout the prostate in men with prostate cancer.
The new guidelines recommend limiting treatment to patients at expected risk for metastatic disease and only evaluating drugs with demonstrated clinical activity. The guidelines also require significant proportion of patients to show decline or no increase in PSA and prostate-cancer specific survival.
A comprehensive review of 72 studies found no evidence that testosterone replacement therapy increases prostate cancer or cardiovascular disease risk. Testosterone therapy may alleviate symptoms of low testosterone levels, but monitoring is crucial due to potential side effects.
Two studies found obesity increases risk of aggressive prostate cancer and cancer recurrence in African-American men. Obesity is associated with higher Gleason scores and elevated PSA levels, suggesting a link between excess body fat and tumor growth.
A study led by Rutgers University professor Mohamed Rafi founds a compound called ß-hydroxy-DHP (BHP) in licorice root supplements that can stop the growth of prostate and breast cancer cells. This could provide new hope for more effective therapies against these leading cancers.
Researchers are investigating the role of broccoli-derived chemicals in preventing prostate cancer. The study aims to better understand how these substances inhibit prostate cancer growth and identify potential biomarkers for future intervention trials.
A new study finds that older men with healthy life expectancy are less likely to receive adequate cancer treatment than younger patients. Despite better prognosis, older prostate cancer patients may not receive important treatments that could extend their life.
A study found that 29.8% of Ontario men diagnosed with prostate cancer used complementary medicine, highlighting the need for awareness and discussion among clinicians. The most commonly used products were natural health supplements like vitamin E, saw palmetto, and selenium, which may interact with conventional therapies.
Researchers found that c-myc promotes androgen-independent growth in prostate cancer cells, slowing growth with downregulation. This suggests a physiological role for c-myc in prostate cancer and offers a possible therapeutic target.
A study of 33 elderly men with advanced prostate cancer found that external beam radiation therapy was well-tolerated and effective in keeping the cancer at bay. The patients experienced no unusual interruptions in treatment due to illness from radiation, and many remained alive and disease-free for several years.
Researchers found that black patients undergoing surgery had a median survival time 1.8 years less than white patients, with disparities smaller among radiation therapy and non-aggressive therapy groups. The study suggests genetic and environmental factors may contribute to these racial disparities in prostate cancer treatment outcomes.
A new campaign, SELECT Sunday, aims to raise awareness of prostate cancer among African-American men, who have the highest incidence rates and a death rate more than double that of white men. The campaign seeks to double African-American enrollment in an international study investigating vitamin E and selenium as preventive measures.
A study published in the Journal of the National Cancer Institute found that rats fed whole tomato powder had a 26% lower risk of prostate cancer death compared to those on control diets. The researchers suggest that whole tomato products and energy balance may offer independent benefits against prostate cancer.
A recent study suggests that lycopene's anti-cancer effect is enhanced by other compounds in tomatoes, such as phytochemicals. Whole tomato consumption was found to offer a lower risk of prostate cancer death compared to dietary supplements.
Researchers at Ohio State University Comprehensive Cancer Center found that a diet rich in whole tomatoes, but not supplements, was associated with longer survival rates and reduced risk of prostate cancer. The study also showed that energy restriction did not offer additional benefits over a balanced diet.
Researchers will study the biology of tumor-stroma interaction, heparan sulfate proteoglycans in bone metastasis, and mitochondrial DNA mutations to develop novel diagnostic and therapeutic strategies. The goal is to understand how prostate cancer cells metastasize to bone and discover new genes that may support or inhibit this process.
Researchers created mouse models to study PTEN's impact on prostate cancer progression. Subtle reductions in PTEN dose produced progressive changes in the biology of tumors, with mice having no functional PTEN genes showing the most invasive and aggressive cancers.
Research studies reveal that weight loss, exercise, and dietary changes can lower breast cancer risk by up to five percent of body weight and increase physical activity levels associated with reduced mammographic breast density. Additionally, a low-carbohydrate diet may be more effective in preventing prostate cancer progression.
Researchers found correlations between cellular features and cancer development in prostate and ovarian cancers. Prostatic intraepithelial neoplasia may be a significant target for prevention strategies.
Scientists at Memorial Sloan-Kettering Cancer Center discovered that the amount of PTEN protein produced affects prostate cancer progression. Mouse models showed varying levels of PTEN protein led to aggressive or benign tumors, suggesting novel clinical strategies for diagnosis, treatment, and prevention.
A study by Pollack and colleagues finds that a high Ki-67 biomarker is linked to increased risk of distant metastasis and death in prostate cancer patients. The researchers also suggest that Ki-67 can help identify high-risk patients who may benefit from alternative treatment strategies.
High doses of radiation therapy directed at the prostate significantly impact cancer control in high-risk patients. The major site of treatment failure is the prostate, highlighting the importance of high doses in this group.
Researchers discovered a genetic link between prostate cancer and a specific gene variant, CYPIBI. The study found that tiny variations in the gene may increase or decrease its cancer-causing effects, leading to a higher risk of developing prostate cancer.
Researchers at Penn aim to understand factors influencing poor prostate cancer outcomes among African-American men, including biological, environmental, and behavioral aspects. The study's findings may help develop better tools for prevention and treatment, ultimately improving clinical outcomes for this underserved population.
A recent study found that men aged 55-74 who received regular prostate cancer screenings every 4 years had a low rate of interval cancers. The screening procedure showed an 85.5% high sensitivity rate for detecting cancers, suggesting that very few aggressive prostate cancers escape screening.
Researchers have created a new method that could detect diseases at earlier stages than possible now, using protein targets like PSA. The method is a million times more sensitive than conventional methods and has the potential to revolutionize cancer diagnostics and treatment.
Prostate cancer mortality rates are falling fast in the US and Europe due to earlier diagnosis and hormonal treatments. Research shows that prompt surgery and hormonal therapy can improve 10-year survival rates for both prostate and breast cancers.
A systematic review and meta-analysis found that men with a family history of prostate cancer have an increased risk of developing the disease. The study revealed a 2.9 fold increased risk when the affected relative was a brother, highlighting the importance of identifying at-risk populations for targeted screening.
A clinical trial found that oral sodium clodronate reduced the risk of symptomatic bone progression by 21% and mortality by 20% compared to placebo, but with limited statistically significant results due to small population size. However, side effects were common, particularly in older patients.
A new nomogram model predicts prostate cancer likelihood in men with PSA levels below 10 ng/ml, helping to reduce unnecessary biopsies. The model identifies four independent risk factors for positive biopsy results and provides a score to calculate the likelihood of cancer presence.
Research identifies three SNPs in PSA gene promoter that increase serum PSA levels, suggesting genotyping may improve prostate cancer detection sensitivity. The findings suggest a lower cutoff value for PSA testing for men with reduced PSA promoter genotype.
A new study identified three genetic variants associated with a 30% increase in prostate-specific antigen (PSA) levels. The discovery could lead to more accurate testing and fewer unnecessary biopsies, particularly for black men who are at higher risk of developing prostate cancer.
Long-term, heavy smoking significantly increases prostate cancer risk in middle-aged men, with double the risk of aggressive forms. Current smokers also face a 40% higher risk compared to nonsmokers.
A new test using ProPSA detected prostate cancer at lower PSA levels, identifying more aggressive forms of the disease. The test improved detection of early aggressive cancer in men who may not have been caught until it was too late.
Researchers found that high zinc intake was associated with an increased risk of advanced prostate cancer, but not with lower doses. The studies also failed to find evidence of simian virus 40 (SV40) DNA in non-Hodgkin's lymphoma samples.
Researchers have identified a genetic marker, MSR1, that increases prostate cancer risk in African-American men. The study, which recruited over 400 black men from Flint, Mich., found that rare germ-line mutations were associated with an increased risk.
A new study by UT Southwestern finds that finasteride effectively reduces prostate cancer risk and improves symptoms in men with benign prostatic hyperplasia. The drug, already used to treat BPH, works by inhibiting the conversion of testosterone to dihydrotestosterone, which is involved in prostate cancer development.
Finasteride has been shown to prevent prostate cancer in both low-risk and high-risk men. However, those on finasteride were more likely to develop high-grade cancers.
The study showed that FDHT-PET detected osseous lesions in patients with advanced metastatic prostate cancer, confirming its utility in evaluating prostate cancer patients. The test also revealed the presence of additional lymph node lesions not identified by CT scans, suggesting its potential to predict response to hormone therapy.
FDHT PET detected 46 lesions, outperforming conventional methods, which identified 59. The agent rapidly absorbed in metastatic lesions indicating functioning androgen receptors. Notably, FDHT uptake reduced in patients starting testosterone therapy.
A new experimental imaging technique has been developed to detect prostate cancer metastases in abdominal lymph nodes. The technique uses advanced high-resolution MR imaging, computerized image analysis, and a novel contrast agent to identify malignant nodes with high accuracy.
Researchers found that increasing RKIP expression in metastatic prostate cancer cells decreased their invasiveness and reduced lung metastases in mice. The study suggests that RKIP may be a suppressor of prostate cancer metastasis, offering new targets for cancer control.
A study suggests that extending screening intervals could reduce lead-time bias and overdetection rates associated with prostate cancer screenings. The research estimates a potential 60-90% increase in prostate cancer incidence, highlighting the need to weigh benefits against risks.
Researchers discovered that a lost protein called PEDF can inhibit angiogenesis, a crucial process for tumor growth, in prostate cancer cells. Treatment with PEDF also triggered increased cell death in cancer cells, suggesting its potential as a new treatment option.
A study of over 78,000 women found that those who worked rotating night shifts for years had a 35% greater risk of developing colorectal cancer. Additionally, research on melanoma suggests two separate pathways may lead to its development, and polymorphisms in certain genes may be associated with prostate cancer risk.
Researchers at M. D. Anderson Cancer Center found that combining Gleevec with chemotherapy resulted in significant drops in PSA levels in some patients, indicating potential therapeutic benefit. The combination therapy showed slow but sustained responses, suggesting a valid target in prostate cancer treatment.
A recent study found that whey protein increased glutathione levels in human prostate cells by up to 64%, potentially protecting against prostate cancer. Whey contains the amino acid cysteine, essential for producing glutathione, which helps control free radicals.
Researchers found that nearly half of men with elevated PSA levels had returned to normal levels after a year or more, making unnecessary biopsies possible. Repeating the PSA test after waiting at least six weeks may reduce unnecessary procedures and small incidental tumors.
Researchers discovered that 3,3'-diindolylmethane (DIM) inhibits the proliferation of human prostate cancer cells by acting as a powerful anti-androgen. DIM, found in cruciferous vegetables like broccoli, decreases PSA levels and blocks the effects of androgen on cancer cells.
Researchers identified a strong association between EZH2 and ECAD biomarkers and prostate cancer recurrence. Moderate or strong expression of EZH2 coupled with at most moderate expression of ECAD is most strongly associated with biochemical recurrence.
A UC Davis study found that a soy extract supplement reduced PSA levels in men with untreated prostate cancer. The study involved 62 men who received genistein concentrated polysaccharide for six months, resulting in an average decrease of 17% in PSA levels.
Blocking the activation of Stat5 in prostate cancer cells triggers extensive cell death, providing a new targeted therapeutic approach to manage cancer growth and metastasis. Prostate cancer is the second leading cause of cancer death in men, with approximately 220,900 new cases expected in the US in 2003.
Researchers have discovered that injecting herpes simplex virus vectors can deliver neurotrophic factors to damaged nerves, improving intracavernous pressure in rats. This concept could translate to humans, enabling gene therapy as a prophylactic treatment for men undergoing radical prostatectomy.
A multi-center study analyzing 2,056 prostate cancer patients found that metastatic disease carries a significant mortality rate and incurs substantial healthcare expenses. Patients with metastatic disease had ten times the death rate of those with localized disease, with $13,650 more in annual healthcare costs.
Researchers discovered that specific p53 mutations facilitate androgen-independent growth in human prostate cells, while another gene, Id-1, promotes tumor aggressiveness. These findings could lead to new therapeutic strategies for hormone-independent prostate cancer.
A new technique developed by Malins' laboratory uses Fourier transform-infrared spectroscopy to analyze DNA from prostate tumor biopsies, allowing doctors to identify patients at high risk for metastasis. This breakthrough enables more informed treatment decisions and potentially saves lives.
Researchers identified lifestyle factors that predict prostate cancer recurrence in treated patients. Patients with low body mass index, regular exercise, and annual screenings had lower risk of progression.
Researchers found that 11C-acetate PET scans were more sensitive than 18F-FDG PET scans in detecting recurrent prostate cancer. The study used 46 patients with detectable serum PSA, and the imaging procedures were conducted on the same day.